VENLAFAXINE XR AND ARIPIPRAZOLE IN PATIENTS WITH DEPRESSION

文拉法辛 XR 和阿立哌唑治疗抑郁症患者

• 批准号: 7625649
• 负责人: BRADLEY N GAYNES
• 金额: $ 1.43万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625649
• 关键词: Adult; Adverse effects; Age; Combination Medication; Computer Retrieval of Information on Scientific Projects Database; Diagnosis; Disease remission; Enrollment; Funding; Grant; Institution; Mental Depression; Patients; Rate; Research; Research Personnel; Resources; Site; Source; United States National Institutes of Health; Week; aripiprazole; interest; venlafaxine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective if this study is to evaluate and assess the tolerability, side effect profile, and rate of remission with the medication combination Venlafaxine XR and Aripiprazole in patients diagnosed with MDD. In all, 250 adult subjects with MDD, between the ages of 18 and 65, may be screened for participation total. Not all subjects screened will be eligible or interested in this study. Enrollment will be competitive. We expect to enroll a total of 50 subjects, no more than 25 at any Regional Center. At this site we hope to enroll 25 subjects. The study enrollment period will last for two or three months and patients will remain in treatment for 12 weeks for an active study lenght of 5-6 months.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的是评价和评估文拉法辛XR和阿立哌唑联合用药在诊断为MDD的患者中的耐受性、副作用特征和缓解率。 总共有250例年龄在18 - 65岁之间的MDD成人受试者可接受总体参与筛选。 并非所有筛选的受试者都有资格参加本研究或对本研究感兴趣。 招生将具有竞争力。 我们预计共入组50例受试者，任何区域中心均不超过25例。 在该研究中心，我们希望入组25例受试者。 研究入组期将持续2或3个月，患者将继续接受12周治疗，有效研究时间为5-6个月。